A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant

Janina Jiang, Guangchao Liu, Valerie A. Kickhoefer, Leonard H. Rome, Lin Xi Li, Stephen J Mcsorley, Kathleen A. Kelly

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chlamydia trachomatis genital infection is the most common sexually transmitted bacterial disease, causing a significant burden to females due to reproductive dysfunction. Intensive screening and antibiotic treatment are unable to completely prevent female reproductive dysfunction, thus, efforts have become focused on developing a vaccine. A major impediment is identifying a safe and effective adjuvant which induces cluster of differentiation 4 (CD4) cells with attributes capable of halting genital infection and inflammation. Previously, we described a natural nanocapsule called the vault which was engineered to contain major outer membrane protein (MOMP) and was an effective vaccine which significantly reduced early infection and favored development of a cellular immune response in a mouse model. In the current study, we used another chlamydial antigen, a polymorphic membrane protein G-1 (PmpG) peptide, to track antigen-specific cells and evaluate, in depth, the vault vaccine for its protective capacity in the absence of an added adjuvant. We found PmpG-vault immunized mice significantly reduced the genital bacterial burden and histopathologic parameters of inflammation following a C. muridarum challenge. Immunization boosted antigen-specific CD4 cells with a multiple cytokine secretion pattern and reduced the number of inflammatory cells in the genital tract making the vault vaccine platform safe and effective for chlamydial genital infection. We conclude that vaccination with a Chlamydia-vault vaccine boosts antigen-specific immunities that are effective at eradicating infection and preventing reproductive tract inflammation.

Original languageEnglish (US)
Article number3
JournalVaccines
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Chlamydia Infections
Nanoparticles
Vaccines
Membrane Proteins
Infection
Inflammation
Antigens
Bacterial Sexually Transmitted Diseases
CD Antigens
Nanocapsules
Reproductive Tract Infections
Chlamydia
Chlamydia trachomatis
Cellular Immunity
Cell Differentiation
Immunity
Immunization
Vaccination
Cell Count
Cytokines

Keywords

  • CD4
  • Chlamydia
  • Infectious diseases
  • Mucosal immunology
  • Tetramer
  • Vaults

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant. / Jiang, Janina; Liu, Guangchao; Kickhoefer, Valerie A.; Rome, Leonard H.; Li, Lin Xi; Mcsorley, Stephen J; Kelly, Kathleen A.

In: Vaccines, Vol. 5, No. 1, 3, 01.03.2017.

Research output: Contribution to journalArticle

Jiang, Janina ; Liu, Guangchao ; Kickhoefer, Valerie A. ; Rome, Leonard H. ; Li, Lin Xi ; Mcsorley, Stephen J ; Kelly, Kathleen A. / A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant. In: Vaccines. 2017 ; Vol. 5, No. 1.
@article{4c317d22d47f4bc28577b62118a8c035,
title = "A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant",
abstract = "Chlamydia trachomatis genital infection is the most common sexually transmitted bacterial disease, causing a significant burden to females due to reproductive dysfunction. Intensive screening and antibiotic treatment are unable to completely prevent female reproductive dysfunction, thus, efforts have become focused on developing a vaccine. A major impediment is identifying a safe and effective adjuvant which induces cluster of differentiation 4 (CD4) cells with attributes capable of halting genital infection and inflammation. Previously, we described a natural nanocapsule called the vault which was engineered to contain major outer membrane protein (MOMP) and was an effective vaccine which significantly reduced early infection and favored development of a cellular immune response in a mouse model. In the current study, we used another chlamydial antigen, a polymorphic membrane protein G-1 (PmpG) peptide, to track antigen-specific cells and evaluate, in depth, the vault vaccine for its protective capacity in the absence of an added adjuvant. We found PmpG-vault immunized mice significantly reduced the genital bacterial burden and histopathologic parameters of inflammation following a C. muridarum challenge. Immunization boosted antigen-specific CD4 cells with a multiple cytokine secretion pattern and reduced the number of inflammatory cells in the genital tract making the vault vaccine platform safe and effective for chlamydial genital infection. We conclude that vaccination with a Chlamydia-vault vaccine boosts antigen-specific immunities that are effective at eradicating infection and preventing reproductive tract inflammation.",
keywords = "CD4, Chlamydia, Infectious diseases, Mucosal immunology, Tetramer, Vaults",
author = "Janina Jiang and Guangchao Liu and Kickhoefer, {Valerie A.} and Rome, {Leonard H.} and Li, {Lin Xi} and Mcsorley, {Stephen J} and Kelly, {Kathleen A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.3390/vaccines5010003",
language = "English (US)",
volume = "5",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant

AU - Jiang, Janina

AU - Liu, Guangchao

AU - Kickhoefer, Valerie A.

AU - Rome, Leonard H.

AU - Li, Lin Xi

AU - Mcsorley, Stephen J

AU - Kelly, Kathleen A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Chlamydia trachomatis genital infection is the most common sexually transmitted bacterial disease, causing a significant burden to females due to reproductive dysfunction. Intensive screening and antibiotic treatment are unable to completely prevent female reproductive dysfunction, thus, efforts have become focused on developing a vaccine. A major impediment is identifying a safe and effective adjuvant which induces cluster of differentiation 4 (CD4) cells with attributes capable of halting genital infection and inflammation. Previously, we described a natural nanocapsule called the vault which was engineered to contain major outer membrane protein (MOMP) and was an effective vaccine which significantly reduced early infection and favored development of a cellular immune response in a mouse model. In the current study, we used another chlamydial antigen, a polymorphic membrane protein G-1 (PmpG) peptide, to track antigen-specific cells and evaluate, in depth, the vault vaccine for its protective capacity in the absence of an added adjuvant. We found PmpG-vault immunized mice significantly reduced the genital bacterial burden and histopathologic parameters of inflammation following a C. muridarum challenge. Immunization boosted antigen-specific CD4 cells with a multiple cytokine secretion pattern and reduced the number of inflammatory cells in the genital tract making the vault vaccine platform safe and effective for chlamydial genital infection. We conclude that vaccination with a Chlamydia-vault vaccine boosts antigen-specific immunities that are effective at eradicating infection and preventing reproductive tract inflammation.

AB - Chlamydia trachomatis genital infection is the most common sexually transmitted bacterial disease, causing a significant burden to females due to reproductive dysfunction. Intensive screening and antibiotic treatment are unable to completely prevent female reproductive dysfunction, thus, efforts have become focused on developing a vaccine. A major impediment is identifying a safe and effective adjuvant which induces cluster of differentiation 4 (CD4) cells with attributes capable of halting genital infection and inflammation. Previously, we described a natural nanocapsule called the vault which was engineered to contain major outer membrane protein (MOMP) and was an effective vaccine which significantly reduced early infection and favored development of a cellular immune response in a mouse model. In the current study, we used another chlamydial antigen, a polymorphic membrane protein G-1 (PmpG) peptide, to track antigen-specific cells and evaluate, in depth, the vault vaccine for its protective capacity in the absence of an added adjuvant. We found PmpG-vault immunized mice significantly reduced the genital bacterial burden and histopathologic parameters of inflammation following a C. muridarum challenge. Immunization boosted antigen-specific CD4 cells with a multiple cytokine secretion pattern and reduced the number of inflammatory cells in the genital tract making the vault vaccine platform safe and effective for chlamydial genital infection. We conclude that vaccination with a Chlamydia-vault vaccine boosts antigen-specific immunities that are effective at eradicating infection and preventing reproductive tract inflammation.

KW - CD4

KW - Chlamydia

KW - Infectious diseases

KW - Mucosal immunology

KW - Tetramer

KW - Vaults

UR - http://www.scopus.com/inward/record.url?scp=85016885323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016885323&partnerID=8YFLogxK

U2 - 10.3390/vaccines5010003

DO - 10.3390/vaccines5010003

M3 - Article

AN - SCOPUS:85016885323

VL - 5

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 3

ER -